Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant To Standard Treatment Of Chemoradiation Therapy

ARLINGTON, Va.--(BUSINESS WIRE)--Castle Biosciences Inc. today announced that results from a second validation study of its proprietary multi-analyte test, DecisionDx-EC, confirmed the test’s ability to identify which esophageal cancer patients are unlikely to benefit from the standard pre-surgical treatment of chemoradiation. The results were reviewed today in an oral presentation at the 11th Annual Meeting of the International Society of Gastrointestinal Oncology in Arlington, Virginia. The results suggest that up to 30% of esophageal cancer patients may not benefit from the highly toxic, pre-surgical chemoradiation therapy (CTRT), and instead could have the option of moving directly to surgery and to other treatment options.

Help employers find you! Check out all the jobs and post your resume.